View Filing Data

BALANCE SHEETS - USD ($) $ in Thousands	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008	Dec. 31, 2007
Current assets
Cash and cash equivalents	$ 112,572	$ 207,075	$ 247,796	$ 498,925
Marketable securities	136,796	134,255
Accounts receivable from the sanofi-aventis Group	79,603	62,703
Accounts receivable - other	13,509	2,865
Prepaid expenses and other current assets	15,142	18,610
Total current assets	357,622	425,508
Restricted cash and marketable securities	7,518	1,600
Marketable securities	370,053	47,080
Property, plant, and equipment, at cost, net of accumulated depreciation and amortization	347,450	259,676
Other assets	6,789	7,338
Current liabilities
Accounts payable and accrued expenses	53,658	49,031
Deferred revenue from sanofi-aventis, current portion	19,506	17,523
Deferred revenue - other, current portion	35,217	27,021
Deferred revenue - other	188,775	46,951
Other long term liabilities	7,350	3,959
Total liabilities	561,617	344,440
Stockholders' equity
Preferred stock, $.01 par value; 30,000,000 shares authorized; issued and outstanding-none	2	2
Common Stock	87	79
Additional paid-in capital	1,575,780	1,336,732
Total stockholders' equity	527,815	396,762	421,514	459,348
Class A [Member]
Stockholders' equity
Common Stock	2	2
Total stockholders' equity	$ 2	$ 2	$ 2	$ 2

Summary of Significant Accounting Policies	12 Months Ended
Summary of Significant Accounting Policies	Dec. 31, 2010
Notes to Financial Statements [Abstract]
Summary of Significant Accounting Policies	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Summary of Significant Accounting Policies/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Cash and Cash Equivalents t;/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"For purposes of the statement of cash flows and the balance sheet, the Company considers all highly liquid debt instruments with a maturity of three months or less when purchased to be cash equivalents.#160;#160;The carrying amount reported in the balance sheet for cash and cash equivalents approximates its fair value./font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"/fontbr /#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify" lt;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Marketable Securities/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company has an investment policy that includes guidelines on acceptable investment securities, minimum credit quality, maturity parameters, and concentration and diversification. The Company has invested its excess cash primarily in direct obligations of the U.S. government and its agencies, other debt securities guaranteed by the U.S. government, and money market funds that invest in U.S. Government securities.#160;#160;The Company considers its marketable securities to be #8220;available-for-sale,#8221; as defined by authoritative guidance issued by the Finan cial Accounting Standards Board (#8220;FASB#8221;).#160;#160;These assets are carried at fair value and the unrealized gains and losses are included in other accumulated comprehensive income (loss) as a separate component of stockholders#8217; equity.#160;#160;If the decline in the value of a marketable security in the Company#8217;s investment portfolio is deemed to be other-than-temporary, the Company writes down the security to its current fair value and recognizes a loss that may be charged against income.#160;#160;As described under #8220;Use of Estimates#8221; below, on a quarterly basis, the Company reviews its portfolio of marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost are other-than-temporary./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RI GHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Inventory/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Inventories are stated at the lower of cost or estimated realizable value.#160;#160;The Company determines the cost of inventory using the first-in, first-out, or FIFO, method.#160;#160;The Company capitalizes inventory costs associated with the Company#8217;s products prior to regulatory approval when, based on management#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized; othe rwise, such costs are expensed as research and development.#160;#160;The Company periodically analyzes its inventory levels to identify inventory that may expire prior to expected sale or has a cost basis in excess of its estimated realizable value, and writes-down such inventories as appropriate./font/div/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Property, Plant, and Equipment/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Property, plant, and equipment are stated at cost, net of accumulated depreciation.#160;#160;Depreciation is provided on a straight-line basis over the estimated useful lives of the assets.#160;#160;Expenditures for maintenance and repairs which do not materially extend the useful lives of the assets are charged to expense as incurred.#160;#160;The cost and accumulated depreciation or amortization of assets retired or sold are removed from the respective accounts, and any gain or loss is recognized in operations.#160;#160;The estimated useful lives of property, plant, and equipment are as follows:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="MARGIN-LEFT: 72pt"/fontBuilding and improvements#160;#160;#160;#160;#160;#160;#160 ;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;10-40 years/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="MARGIN-LEFT: 72pt"/fontLaboratory and other equipment#160;#160;#160;#1 60;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;3-10 years/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="MARGIN-LEFT: 72pt"/fontFurniture and fixtures#160;#160;#160;#160;#160;#160;#160;#160; ;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160; 5 years/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIG HT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Leasehold improvements are amortized over the shorter of the estimated useful lives of the assets or the lease term, without assuming renewal features, if any, are exercised.#160;#160;Costs of construction of certain long-lived assets include capitalized interest which is amortized over the estimated useful life of the related asset./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"a id="jump_exp_29" name="jump_exp_29"!--EFPlaceholder--/aa id="jump_exp_30" name="jump_exp_30"!--EFPlaceholder--/aa id="jump_exp_31" name="jump_exp_31"!--EFPlaceholder--/a a id="jump_exp_32" name="jump_exp_32"!--EFPlaceholder--/aAccounting for the Impairment of Long-Lived Assets/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company periodically assesses the recoverability of long-lived assets, such as property, plant, and equipment, and evaluates such assets for impairment whenever events or changes in circumstances indicate that the carrying amount of an asset may not be recoverable.#160;#160;Asset impairment is determined to exist if estimated future undiscounted cash flows are less than the carrying amount.#160;#160;For all periods presented, no impairment losses were recorded./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Patents/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As a result of the Company#8217;s research and development efforts, the Company obtains and applies for patents to protect proprietary technology and inventions.#160;#160;All costs associated with patents for product candidates under development are expensed as incurred.#160;Patent costs related to commercial products are capitalized and amortized over the shorter of their estimated useful life or the remaining patent term.#160;#160;To date, the Company has no capitalized patent costs./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Operating Leases/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"On certain of its operating lease agreements, the Company may receive rent holidays and other incentives. The Company recognizes operating lease costs on a straight-line basis without regard to deferred payment terms, such as rent holidays that defer the commencement date of required payments.#160;#160;In addition, lease incentives that the Company receives are tr eated as a reduction of rent expense over the term of the related agreements./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Revenue Recognition/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"a. Collaboration Revenue/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman" The Company earns collaboration revenue in connection with collaboration agreements to develop and commercialize product candidates and utilize the Company#8217;s technology platforms.#160;#160;The terms of these agreements typically include non-refundable up-front licensing payments, research progress (milestone) payments, and payments for development activities.#160;#160;Non-refundable up-front license payments, where continuing involvement is required of the Company, are deferred and recognized over the related performance period.#160;#160;The Company estimates its performance period based on the specific terms of each agreement, and adjusts the performance periods, if appropriate, based on the applicable facts and circumstances.#160;#160;Payments which are based on achieving a specific performance milestone, involving a degree of risk, are recognized as revenue when the milestone is achieved and the related payment is due and non-refundable, provided there is no future service obligation associated with that milestone.#160; Substantive performance milestones typically consist of significant achievements in the development life-cycle of the related product candidate, such as completion of clinical trials, filing for approval with regulatory agencies, and receipt of approvals by regulatory agencies.#160;#160;In determining whether a payment is deemed to be a substantive performance milestone, the Company takes into consideration (i) the nature, timing, and value of significant achievements in the development life-cycle of the related development product candidate, (ii) the relative level of effort required to achieve the milestone, and (iii) the relative level of risk in achieving the milestone, taking into account the high degree of uncertainty in successfully advancing product candidates in a drug development program and in ultimately attaining an approved drug product.#160; Payments for achieving milestones which are not considered substa ntive are accounted for as license payments and recognized over the related performance period./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company enters into collaboration agreements that include varying arrangements regarding which parties perform and bear the costs of research and development activities.#160;#160;The Company mayfont style="DISPLAY: inline; FONT-WEIGHT: bold"#160;/fontshare the costs of research and development activities with a collaborator, such as in the Company#8217;s VEGF Trap-Eye collaboration with Bayer HealthCare LLC, or the Company may be reimbursed for all or a significant portion of the costs of the Company#8217;s research and development activities, such as in the Company#8217;s afliberc ept and antibody collaborations with the sanofi-aventis Group.#160;#160;The Company records its internal and third-party development costs associated with these collaborations as research and development expenses.#160;#160;When the Company is entitled to reimbursement of all or a portion of the research and development expenses that it incurs under a collaboration, the Company records those reimbursable amounts as collaboration revenue proportionately as the Company recognizes its expenses.#160;#160;If the collaboration is a cost-sharing arrangement in which both the Company and its collaborator perform development work and share costs, in periods when the Company#8217;s collaborator incurs development expenses that benefit the collaboration and Regeneron, the Company also recognizes, as additional research and development expense, the portion of the collaborator#8217;s development expenses that the Company is obligated to reimburse./font/divdiv sty le="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In connection with non-refundable licensing payments, the Company#8217;s performance period estimates are principally based on projections of the scope, progress, and results of its research and development activities.#160;#160;Due to the variability in the scope of activities and length of time necessary to develop a drug product, changes to development plans as programs progress, and uncertainty in the ultimate requirements to obtain governmental approval for commercialization, revisions to performance period estimates are likely to occur periodically, and could result in material changes to the amount of revenue recognized each year in the future.#160;#160;In addition, estimated performance periods may change if development program s encounter delays, or the Company and its collaborators decide to expand or contract the clinical plans for a drug candidate in various disease indications.#160;#160;Also, if a collaborator terminates an agreement in accordance with the terms of the agreement, the Company would recognize any unamortized remainder of an up-front or previously deferred payment at the time of the termination./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"b. font style="DISPLAY: inline; FONT-STYLE: italic"VelocImmune/fontfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: italic"#174; /fontTechnology Licensing/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divd iv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company enters into non-exclusive license agreements with third parties that allow the third party to utilize the Company#8217;s font style="DISPLAY: inline; FONT-STYLE: italic"VelocImmune/fontfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font technology in its internal research programs.#160;#160;The terms of these agreements include up-front payments and entitle the Company to receive royalties on any future sales of products discovered by the third party using the Company#8217;s font style="DISPLAY: inline; FONT-STYLE: italic"VelocImmune/fontfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-STYLE: italic"#174;/fontfont style="DISPLAY: inline; FONT-STYLE: italic" ;#160;/fonttechnology.#160;#160;Up-front payments under these agreements, where continuing involvement is required of the Company, are deferred and recognized ratably over their respective license periods./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"c. Product Revenue/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="MARGIN-LEFT: 18pt"/font#160;Revenue from product sales is recognized when persuasive evidence of an arrangement exists, title to product and associated risk of loss has pa ssed to the customer, the price is fixed or determinable, collection from the customer is reasonably assured, and the Company has no further performance obligations.#160;#160;Revenue and deferred revenue from product sales are recorded net of applicable provisions for prompt pay discounts, product returns, estimated rebates payable under governmental programs (including Medicaid), distribution fees, and other sales-related deductions.#160;#160;The Company reviews its estimates of rebates payable each period and records any necessary adjustments in the current period#8217;s net product sales./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Investment Income/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Interest income, which is included in investment income, is recognized as earned./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Research and Development Expenses/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Research and development expenses include costs directly attributable to the conduct of research and development programs, including the cost of salaries, payroll taxes, employee benefits, materials, supplies, depreciation on and maintenance of research equipment, costs related to research collaboration and licensing agreements, the cost of services provided by outside contractors, including services related to the Company#8217;s clinical trials, clinical trial expenses, the full cost of manufacturing drug for use in research, preclinical development, and clinical trials, amounts that the Company is obligated to reimburse to collaborators for research and development expenses that they incur, and the allocable portions of facility costs, such as rent, utilities, insurance, repairs and maintenance, depreciation, and general support services.#160;#160;All costs associated with research and development are expensed as incurred./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: b lock; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Clinical trial costs are a significant component of research and development expenses and include costs associated with third-party contractors.#160;#160;The Company outsources a substantial portion of its clinical trial activities, utilizing external entities such as contract research organizations (#8220;CROs#8221;), independent clinical investigators, and other third-party service providers to assist the Company with the execution of its clinical studies.#160;#160;For each clinical trial that the Company conducts, certain clinical trial costs are expensed immediately, while others are expensed over time based on the expected total number of patients in the trial, the rate at which patients enter the trial, and/or the period over which clinical investigators or contract research organizations are expected to provide services./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Clinical activities which relate principally to clinical sites and other administrative functions to manage the Company#8217;s clinical trials are performed primarily by CROs.#160;#160;CROs typically perform most of the start-up activities for the Company#8217;s trials, including document preparation, site identification, screening and preparation, pre-study visits, training, and program management.#160;#160;On a budgeted basis, these start-up costs are typically#160;10% to#160;20% of the total contract value.#160;#160;On an actual basis, this percentage range can be significantly wider, as many of the Company#8217;s contracts are either expanded or reduced in scope compared to the original budget, while start-up costs for the particular trial may not change materially.#160;#160;These start-up costs usually occur within a few months after the contract has been executed and are event driven in nature. The remaining activities and related costs, such as patient monitoring and administration, generally occur ratably throughout the life of the individual contract or study. In the event of early termination of a clinical trial, the Company accrues and recognizes expenses in an amount based on its estimate of the remaining non-cancelable obligations associated with the winding down of the clinical trial and/or penalties./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"For clinical study sites, where payments are made perio dically on a per-patient basis to the institutions performing the clinical study, the Company accrues expense on an estimated cost-per-patient basis, based on subject enrollment and activity in each quarter.#160;#160;The amount of clinical study expense recognized in a quarter may vary from period to period based on the duration and progress of the study, the activities to be performed by the sites each quarter, the required level of patient enrollment, the rate at which patients actually enroll in and drop-out of the clinical study, and the number of sites involved in the study.#160;#160;Clinical trials that bear the greatest risk of change in estimates are typically those that have a significant number of sites, require a large number of patients, have complex patient screening requirements, and span multiple years.#160;#160;During the course of a trial, the Company adjusts its rate of clinical expense recognition if actual results differ from the Company#8217;s estimates .#160;#160;The Company#8217;s estimates and assumptions for clinical expense recognition could differ significantly from its actual results, which could cause material increases or decreases in research and development expenses in future periods when the actual results become known./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Stock-based Compensation/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company recognizes stock-based compensation expense for grants of stock option awards and restricted stock under the Company#8217;s Long-Term Incentive Plans, to employees and non-employee members of the Company#8217;s board of directors, based on the grant-date fair value of those awards.#160;#160;The grant-date fair value of an award is generally recognized as compensation expense over the award#8217;s requisite service period.#160;#160;In addition, the Company has granted performance-based stock option awards which vest based upon the optionee satisfying certain performance and service conditions as defined in the agreements.#160;#160;Potential compensation cost, measured on the grant date, related to these performance options will be recognized only if, and when, the Company estimates that these options will vest, which is based on whether the Company consider the options#8217; performance conditions to be probable of attainment.#160;#160;The Company#8217;s estimates of the number of performance-based options that wil l vest will be revised, if necessary, in subsequent periods./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company uses the Black-Scholes model to compute the estimated fair value of stock option awards.#160;#160;Using this model, fair value is calculated based on assumptions with respect to (i) expected volatility of our Common Stock price, (ii) the periods of time over which employees and members of the board of directors are expected to hold their options prior to exercise (expected lives), (iii) expected dividend yield on the Common Stock, and (iv) risk-free interest rates.#160;#160;Stock-based compensation expense also includes an estimate, which is made at the time of grant, of the number of awards that are expected to be forfeited.#16 0;#160;This estimate is revised, if necessary, in subsequent periods if actual forfeitures differ from those estimates./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Income Taxes/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company recognizes deferred tax liabilities and assets for the expected future tax consequences of events that have been included in the financial statements or tax returns.#160;#160;Under this method, deferred tax liabilities and assets are determined on the basis of the difference between the tax basis of assets and liabilities and their respective financial reporting amounts (#8220;temporary differences#8221;) at enacted tax rates in effect for the years in which the differences are expected to reverse.#160;#160;A valuation allowance is established for deferred tax assets for which realization is uncertain./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Uncertain tax positions are accounted for in accordance with FASB authoritative guidance, which prescribes a comprehensive model for the manner in which a company should recognize, measure, present, and disclose in its financial statements all material uncertain tax positions that the company has taken or expects to take on a tax return.#160; mp;#160;Those positions, for which management's assessment is that there is more than a 50% probability of sustaining the position upon challenge by a taxing authority based upon its technical merits, are subjected to certain measurement criteria./font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company#8217;s policy is to recognize interest and penalties related to income tax matters in income tax expense./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Comprehensive Income (Loss)/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br / /divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Comprehensive income (loss) of the Company includes net income (loss) adjusted for the change in net unrealized gain or loss on marketable securities, net of any tax effect.#160;#160;Comprehensive income (loss) for the years ended December 31, 2010, 2009, and 2008 have been included in the Statements of Stockholders#8217; Equity./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Concentration of Credit Risk/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style=" DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="MARGIN-LEFT: 18pt"/fontFinancial instruments which potentially subject the Company to concentrations of credit risk consist of cash, cash equivalents, marketable securities (see Note 6), and receivables from sanofi-aventis./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Per Share Data/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; F ONT-FAMILY: Times New Roman"font style="MARGIN-LEFT: 18pt"/fontNet income (loss) per share, basic and diluted, is computed on the basis of the net income (loss) for the period divided by the weighted average number of shares of Common Stock and Class A Stock outstanding during the period.#160;#160;Basic net income (loss) per share excludes restricted stock awards until vested.#160;#160;Diluted net income per share is based upon the weighted average number of shares of Common Stock and Class A Stock outstanding, and of common stock equivalents outstanding when dilutive.#160;#160;Common stock equivalents include: (i) outstanding stock options and restricted stock awards under the Company#8217;s Long-Term Incentive Plans, which are included under the #8220;treasury stock method#8221; when dilutive, and (ii) Common Stock to be issued under the assumed conversion of the Company#8217;s formerly outstanding convertible senior subordinated notes, which are included under the #8220;if-converted method#8221; when dilutive.#160;#160;The computation of diluted net loss per share for the years ended December 31, 2010, 2009, and 2008 does not include common stock equivalents, since such inclusion would be antidilutive./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Risks and Uncertainties/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Developing and commercializing new medicines entails significant risk and expense.#160 ;#160;Since its inception, the Company has not generated any significant sales or profits from the commercialization of ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-FAMILY: Symbol, serif"#210;/font or any of the Company#8217;s other product candidates.#160;#160;Before revenues from the commercialization of the Company#8217;s current or future product candidates can be realized, the Company (or its collaborators) must overcome a number of hurdles which include successfully completing research and development and obtaining regulatory approval from the FDA and regulatory authorities in other countries.#160;#160;In addition, the biotechnology and pharmaceutical industries are rapidly evolving and highly competitive, and new developments may render the Company#8217;s products and technologies uncompetitive or obsolete.#160;#160;The Company may be subject to legal claims by third parties seeking to enforce patents to limit or prohibit the Company from marketing or selling its products.#160;#160;The Company is also dependent upon the services of its employees, consultants, collaborators, and certain third-party suppliers, including single-source unaffiliated third-party suppliers of certain raw materials and equipment. Regeneron, as licensee, licenses certain technologies that are important to the Company#8217;s business which impose various obligations on the Company.#160;#160;If Regeneron fails to comply with these requirements, licensors may have the right to terminate the Company#8217;s licenses./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company has generally incurred net losses and negative cash flows from operations since its in ception.#160;#160;Revenues to date have principally been limited to (i) up-front, license, milestone, and reimbursement payments from the Company#8217;s collaborators and other entities related to the Company#8217;s development activities and technology platforms, (ii) payments for past contract manufacturing activities, (iii) ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font product sales, and (iv) investment income.#160;#160;Collaboration revenue in 2010 was earned from sanofi-aventis and Bayer HealthCare under collaboration agreements (see Note 3 for the terms of these agreements).#160;#160;These collaboration agreements contain early termination provisions that are exercisable by sanofi-aventis or Bayer HealthCare, as applicable./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT : 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Use of Estimates/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes.#160;#160;Actual results could differ from those estimates.#160;#160;Estimates which could have a significant impact on the Company#8217;s financial statements include:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 27pt" align="right"divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"#183;#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Product rebates and returns in connection with the recognition of revenue from product sales./font/div/td/tr/table/divdivtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 27pt" align="right"divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"#183;#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" alig n="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Periods over which payments, including non-refundable up-front, license, and milestone payments, are recognized as revenue in connection with collaboration and other agreements to develop and commercialize product candidates and utilize the Company#8217;s technology platforms./font/div/td/tr/table/divdivtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 27pt" align="right"divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"#183;#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Periods over which certain clinical trial costs, including costs for clini cal activities performed by contract research organizations, are recognized as research and development expenses./font/div/td/tr/table/divdivtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 27pt" align="right"divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"#183;#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In connection with stock option awards, (i) the fair value of stock options on their date of grant using the Black-Scholes option-pricing model, based on assumptions with respect to (a) expected volatility of the Company#8217;s Common Stock price, (b) the periods of time for which employees and members of the Company#8217;s board of directors are expected to hold their options prior to exercise (expected lives), (c) expected dividend yield on the Company#8217;s Common Stock, and (d) risk-free interest rates, which are based on quoted U.S. Treasury rates for securities with maturities approximating the options#8217; expected lives; (ii) the number of stock option awards that are expected to be forfeited; and (iii) with respect to performance-based stock option awards, if and when the options#8217; performance conditions are considered to be probable of attainment./font/div/td/tr/table/divdivtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 27pt" align="right"divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"#183;#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0p t" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company#8217;s determination of whether marketable securities are other than temporarily impaired.#160;#160;The Company conducts a quarterly review of its portfolio of marketable securities, using both quantitative and qualitative factors, to determine, for securities whose current fair value is less than their cost, whether the decline in fair value below cost is other-than-temporary.#160;#160;In making this determination, the Company considers factors such as the length of time and the extent to which fair value has been less than cost, financial condition and near-term prospects of the issuer, recommendations of investment advisors, and forecasts of economic, market, or industry trends.#160;#160;This review process also includes an evaluation of the Company#8217;s ability and intent to hold individual securities until they mature or their full value can be re covered.#160;#160;This review is subjective and requires a high degree of judgment./font/div/td/tr/table/divdivtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 27pt" align="right"divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"#183;#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Useful lives of property, plant, and equipment./font/div/td/tr/table/divdivtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 27pt" align="right"divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, ser if"#183;#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Capitalized inventory costs associated with the Company#8217;s products prior to regulatory approval when, based on management#8217;s judgment, future commercialization is considered probable and the future economic benefit is expected to be realized./font/div/td/tr/table/divdivtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 27pt" align="right"divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Symbol, serif"#183;#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPL AY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The extent to which deferred tax assets and liabilities are offset by a valuation allowance./font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In addition, the Company#8217;s share of VEGF Trap-Eye development expenses incurred by Bayer HealthCare, including the Company#8217;s share of Bayer HealthCare#8217;s estimated VEGF Trap-Eye development expenses for the most recent fiscal quarter, are included in research and development expenses.#160;#160;The Bayer HealthCare estimate for the most recent fiscal quarter is adjusted in the subsequent quarter to reflect actual expenses for the quarter./font/divdiv style="DISPLAY: bl ock; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Future Impact of Recently Issued Accounting Standards/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In October 2009, the FASB amended its authoritative guidance on multiple-deliverable revenue arrangements.#160;#160;The amended guidance provides greater ability to separate and allocate consideration to be received in a multiple-element revenue arrangement by requiring the use of estimated selling prices to allocate the consideration, thereby eliminating the use of the residual method of a llocation.#160;#160;The amended guidance also requires expanded qualitative and quantitative disclosures surrounding multiple-deliverable revenue arrangements.#160;#160;This guidance may be applied retrospectively or prospectively for new or materially modified arrangements.#160;#160;The Company will adopt this amended guidance effective for the fiscal year beginning January 1, 2011.#160;#160;Management does not anticipate that the adoption of this guidance will have a material impact on the Company#8217;s financial statements./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In March 2010, the FASB amended its authoritative guidance on the milestone method of revenue recognition.#160;#160;The milestone method of reven ue recognition has now been codified as an acceptable revenue recognition model when a milestone is deemed to be substantive.#160;#160;This guidance may be applied retrospectively to all arrangements or prospectively for milestones achieved after the adoption of the guidance.#160;#160;The Company will adopt this amended guidance for the fiscal year beginning January 1, 2011.#160;#160;Management does not anticipate that the adoption of this guidance will have a material impact on the Company#8217;s financial statements./font/div

Marketable Securities	12 Months Ended
Marketable Securities	Dec. 31, 2010
Notes to Financial Statements [Abstract]
Marketable Securities	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"6.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Marketable Securities/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Marketable securities at December 31, 2010 and 2009 consisted of debt securities, as detailed b elow, and equity securities, the aggregate fair value of which was $3.6 million and $5.5 million at December 31, 2010 and 2009, respectively, and the aggregate cost basis of which was $4.0 million at both December 31, 2010 and 2009.#160;#160;The Company also held restricted marketable securities at December 31, 2010, which consisted of debt securities, as detailed below, that collateralize (i) a letter of credit in connection with the Company#8217;s lease of facilities in Tarrytown, New York and (ii) capital lease obligations.#160;#160;See Note 11a.#160;#160;The Company held no restricted marketable securities at December 31, 2009./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The following tables summarize the amortized cost basis of debt securities included in marketable securities, the aggregate fair value of those securities, and gross unrealized gains and losses on those securities at December 31, 2010 and 2009.#160;#160;The Company classifies its debt securities, other than mortgage-backed securities, based on their contractual maturity dates.#160;#160;Maturities of mortgage-backed securities have been estimated based primarily on repayment characteristics and experience of the senior tranches that the Company holds./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd valign="top" width="30%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; F ONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Amortized/font/div/tdtd valign="top" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;Fair/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="31%" colspan="3"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Unrealized/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"At December 31, 2010/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Cost Basis/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;font st yle="DISPLAY: inline"Value/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;#160;font style="DISPLAY: inline"Gains/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;font style="DISPLAY: inline"(Losses)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" wi dth="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;font style="DISPLAY: inline"Net/font/font/div/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"Unrestricted/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new r oman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Maturities within one year/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style ="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government obligations/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" alig n="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$83,635/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$83,684/font/div/tdtd valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$54/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$(5)/font/div/tdtd valign="top" align="right" width="11%" colspan="2" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$49/font/div/td/trtrtd valign="top" align="left" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government guaranteed corporate bonds/font/div/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"48,173/font/div/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"48,531/font/div/tdtd valign="bottom" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"358/font/div/tdtd valign="bottom" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"358/font/div/td/trtrtd valign="bottom" align="left" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government guaranteed collateralized mortgage obligations/font/div/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,027/font/div/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,131/font/div/tdtd valign="bottom" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"104/font/div/tdtd valign="bottom" width="11 %"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"104/font/div/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Municipal bonds/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,597/font/div/tdtd valign="top" align="right" wid th="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,603/font/div/tdtd valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6/font/div/td/trtrtd valign="top" width="30%"div style="DISP LAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Mortgage-backed securities/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"875/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"847/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align=" right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(28)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(28)/font/font/div/td/trtrtd val ign="top" width="30%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"136,307/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"136,796/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT : 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"522/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(33)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"489/font/font/div/td/trtrtd valign="top" width="30%"div style="D ISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Maturities between one and five years/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td lt;/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government obligations/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"352,345/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"350,683/font/div/tdtd valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"fon t style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"64/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(1,726)/font/div/tdtd valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(1,662)/font/div/td/trtrtd valign="top" align="left" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government guaranteed corporate bonds/font/div/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"15,522/font/div/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"15,477/font/div/tdtd valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(45)/font/div/tdtd valign="bottom" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(45)/font/div/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Mortgage-backed securities/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"110/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div sty le="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"38/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(72)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width ="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(72)/font/font/div/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"367,977/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="righ t" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"366,198/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"64/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(1,843)/font/font/div/td td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(1,779)/font/font/div/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Maturities between five and seven years/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Mortgage-backed securities/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"284/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"243/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FO NT-FAMILY: times new roman"font style="DISPLAY: inline"(41)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(41)/font/font/div/td/trtrtd valign="top" width="30%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"504,568/font/font/div ;/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"503,237/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"586/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(1,917)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(1,331)/font/font/div/td/trtrtd valign="top" width="30%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10p t; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"Restricted/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd v align="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Maturities within one year/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: tim es new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government obligations/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline ; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,922/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,921/font/div/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(1)/font/div/tdtd valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(1)/font/div/td/trtrtd valign="top" width="30%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/tr t;trtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Maturities between one and three years/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMI LY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government obligations/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"4,135/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"4,118/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(17)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-F AMILY: times new roman"font style="DISPLAY: inline"(17)/font/font/div/td/trtrtd valign="top" width="30%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"7,057/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"7,039/font/font/div/tdt d style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(18)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(18)/font/f ont/div/td/trtrtd valign="top" width="30%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" w idth="30%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$511,625/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$510,276/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$586/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$(1,935)/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$(1,349)/font/font/div/td/trtrtd valign="top" width="30%"font s tyle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/tr/table/divdivtable cellspacing="0" cellpadding="0" width="100%"trtd valign="top" wi dth="30%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="31%" colspan="3"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SI ZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"At December 31, 2009/font/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT : 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"Unrestricted/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd vali gn="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Maturities within one year/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#1 60; /font/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;U.S. government obligations/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$100,491/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$100,573/font/div/tdtd valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$82/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$82/font/div/td/trtrtd valign="top" align="left" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government guaranteed corporate bonds/font/div/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MA RGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"17,176/font/div/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"17,340/font/div/tdtd valign="bottom" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"164/font/div/tdtd valign="bottom" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TE XT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"164/font/div/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;Corporate bonds/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"10,142/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"10,342/font ;/div/tdtd valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"200/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"200/font/div/td/trtrtd valign="bottom" align="left" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government guaranteed coll ateralized mortgage obligations/font/div/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,612/font/div/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,662/font/div/tdtd valign="bottom" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"50/font/div/tdtd valign="bottom" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" amp;#160; /font/tdtd valign="bottom" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"50/font/div/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;Mortgage-backed securities/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2,471/font/font/div/tdtd styl e="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2,338/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$(133)/font/font/div /tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(133)/font/font/div/td/trtrtd valign="top" width="30%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"133,892/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"134,255/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"496/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(133)/font/font/div/tdtd style="BORDER-BO TTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"363/font/font/div/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Maturities between one and two years/font/div/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style= "DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;U.S. government obligations/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"9,413/font/div/td ;td valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"9,367/font/div/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(46)/font/div/tdtd valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(46)/font/div/td/trtrtd val ign="top" align="left" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government guaranteed corporate bonds/font/div/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"31,064/font/div/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"31,344/font/div/tdtd valign="bottom" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right" font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"280/font/div/tdtd valign="bottom" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"280/font/div/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;Mortgage-backed securities/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0p t; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"1,168/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"900/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(268)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(268)/font/font/div/td/trtrtd valign="top" width="30%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="D ISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"41,645/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"41,611/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"280/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(314)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(34)/font/font/div/td/trtrtd valign="top" width="30%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font ;/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="30%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$175,537/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$175,866/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$776/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TE XT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$(447)/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$329/font/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"At December 31, 2010 and 2009, marketable securities included an additional unrealized loss of $0.4 million and an addi tional unrealized gain of $1.4 million, respectively, related to one equity security in the Company#8217;s marketable securities portfolio./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The following table shows the fair value of the Company#8217;s marketable securities that have unrealized losses and that are deemed to be only temporarily impaired, aggregated by investment category and length of time that the individual securities have been in a continuous unrealized loss position, at December 31, 2010 and 2009.#160;#160;The debt securities listed at December 31, 2010, excluding mortgage-backed securities, mature at various dates through November 2013.#160;#160;The mortgage-backed securities listed at December 31, 2010 mature at various da tes through January 2017./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd valign="top" width="24%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="20%" colspan="2"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Less than 12 Months/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="19%" colspan="2"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARG IN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"12 Months or Greater/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="20%" colspan="2"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Total/font/font/div/td/trtrtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="24%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"fon t style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"At December 31, 2010/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Fair Value/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDEN T: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Unrealized font style="DISPLAY: inline"Loss/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="9%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Fair Value/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/divdiv style ="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Unrealized font style="DISPLAY: inline"Loss/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Fair Value/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" lt;/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Unrealized font style="DISPLAY: inline"Loss/font/font/div/td/trtrtd valign="top" align="left" width="24%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"Unrestricted/font/div/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="9%"font style="DISPL AY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="24%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government obligations/font/div/tdtd valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"f ont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$340,444/font/div/tdtd valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$(1,731)/font/div/tdtd valign="top" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$340,444/font/div/tdtd valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$(1,731)/font/div/td/trtrtd valign="top" width="24%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government guaranteed/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;corporate bonds/font/div/tdtd valign="bottom" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"19,005/font/div/tdtd valign="bottom" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(45)/font/div/tdtd valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"19,005/font/div/tdtd valign="bottom" align="right" width="10%"div style="DISPLAY: block; MARGI N-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(45)/font/div/td/trtrtd valign="top" width="24%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Equity security/font/div/tdtd valign="bottom" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,612/font/div/tdtd valign="bottom" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(433)/font /div/tdtd valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,612/font/div/tdtd valign="bottom" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"(433)/font/div/td/trtrtd valign="top" width="24%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Mortgage-backed securities/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="9%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right" lt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$1,128/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$(141)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"1,128/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: bloc k; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(141)/font/font/div/td/trtrtd valign="top" width="24%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"363,061/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: blo ck; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(2,209)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="9%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"1,128/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(141)/font/font/div/tdtd style="BORDER-BOTTOM: black 2 px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"364,189/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(2,350)/font/font/div/td/trtrtd valign="top" width="24%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td td valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="24%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new r oman"Restricted/font/div/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="24% "div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;U.S. government obligations/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"6,154/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(18)/font/font/div/td td style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="9%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"6,154/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(18)/font/font/div/td/trtrtd valign="top" width="24%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"6,154/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN - -LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(18)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="9%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"6,154/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(18)/font/font/div/td/trtrtd valign="top" width="24%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: time s new roman"#160; /font/tdtd valign="top" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="24%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="rig ht"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$369,215/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$(2,227)/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="9%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$1,128/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"div styl e="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$(141)/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$370,343/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$(2,368)/font/font/div/td/tr trtd valign="top" width="24%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: ti mes new roman"#160; /font/td/trtrtd valign="top" width="24%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%" gt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="24%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"At December 31, 2009/font/font/div/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%" t;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="24%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government obligations/font/div/tdtd valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$9,367/font/div/tdtd valign= "top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$(46)/font/div/tdtd valign="top" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$9,367/font/div/tdtd valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPL AY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$(46)/font/div/td/trtrtd valign="top" width="24%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Mortgage-backed securities/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font mp;#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="9%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$3,238/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$(401)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"3,238/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(401)/font/font/div/td/trtrtd valign="top" width="24%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$9,367/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$(46)/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="9%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 10.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$3,238/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 8.35pt " align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$(401)/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$12,605/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 9.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$(447)/font/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt" br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Realized gains and losses are included as a component of investment income.#160;#160;For the year ended December 31, 2010, realized losses on sales of marketable securities totaled $0.2 million and realized gains on sales of marketable securities were not significant.#160;#160;For the years ended December 31, 2009 and 2008, realized gains on sales of marketable securities totaled $0.2 million and $1.2 million, respectively, and realized losses on sales of marketable securities were not significant.#160;#160;In computing realized gains and losses, the Company computes the cost of its investments on a specific identification basis.#160;#160;Such cost includes the direct costs to acquire the security, adjusted for the amortization of any discount or premium./font /divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company#8217;s assets that are measured at fair value on a recurring basisfont style="DISPLAY: inline; FONT-STYLE: italic",/font at December 31, 2010 and 2009, were as follows:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd valign="top" width="29%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIG N: center" valign="top" width="39%" colspan="3"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Fair Value Measurements at Reporting Date Using/font/font/div/td/trtrtd valign="bottom" width="29%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"Fair Value/font/font/div/td td style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Quoted Prices in Active /font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Markets for Identical Assets/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(Level 1)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-I NDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Significant Other Observable Inputs/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(Level 2)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Significant Unobservable Inputs/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(Level 3)/font/font/div/td/trtrtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"At December 31, 2010/font/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"Unrestricted/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" gt;#160; /font/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Available-for-sale marketable securities/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top " align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government obligations/font/div/tdtd valign="bottom" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$434,367/font/div/tdtd valign="bottom" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$434,367/font/div/tdtd valign="top" wi dth="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government guaranteed corporate bonds/font/div/tdtd valign="bottom" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"64,008/font/div/tdtd valign="bottom" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"64,008/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government guaranteed collateralized mortgage obligations/font/div/tdtd valign="bottom" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,131/font/div/tdtd valign="bottom" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2,131/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Municipal bonds/font/div/tdtd valign="bottom" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-S IZE: 10pt; FONT-FAMILY: times new roman"1,603/font/div/tdtd valign="bottom" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,603/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Mortgage-backed securities/font/div/tdtd valign="bottom" align="r ight" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,128/font/div/tdtd valign="bottom" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"1,128/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font styl e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Equity security/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"3,612/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$3,612/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RI GHT: 14.4pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="29%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"506,849/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIG HT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"3,612/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"503,237/font/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="29%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#1 60; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: times new roman"Restricted/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT- SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Available-for-sale marketable securities/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd vali gn="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 9pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government obligations/font/div/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="top" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;font style="DISPLAY: inline"7,039/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 36pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"#160;7,039/font/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="29%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font /tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" width="29%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$513,888/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="bottom" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$3,612/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="bottom" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$510,276/font/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#16 0; /font/td/trtrtd valign="top" width="29%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left" font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"At December 31, 2009/font/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Available-for-sale marketable securities/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government obligations /font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$109,940/font/div/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$109,940/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 18pt ; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government guaranteed corporate bonds/font/div/tdtd valign="bottom" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"48,684/font/div/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="bottom" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"48,684/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FO NT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Corporate bonds/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"10,342/font/div/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: t imes new roman"10,342/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"U.S. government guaranteed collateralized mortgage obligations/font/div/tdtd valign="bottom" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,662/font/div/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="botto m" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,662/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Mortgage-backed securities/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,238/font/div/tdtd valign ="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,238/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Equity security/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDE NT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"5,469/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$5,469/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new rom an"#160; /font/td/trtrtd valign="top" width="29%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$181,335/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$5,469/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align=" right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.4pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$175,866/font/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Marketable securities included in Level 2 were valued using a market approach utilizing prices and other relevant information, such as interest rates, yield curves, prepayment speeds, loss severities, credit risks and default rates, generated by market transaction s involving identical or comparable assets.#160;#160;The Company considers market liquidity in determining the fair value for these securities.#160;#160;During each of the years ended December 31, 2010 and 2008, deterioration in the credit quality of a marketable security subjected the Company to the risk of not being able to recover the carrying value of these securities.#160;#160;As a result, the Company recognized a $0.1 million and $1.8 million impairment charge related to its Level 2 marketable securities for the years ended December 31, 2010 and 2008, respectively, which the Company considered to be other-than-temporarily impaired.#160;#160;During the year ended December 31, 2009, the Company did not record any charges for other-than-temporary impairment of its Level 2 marketable securities./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN - -RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company held one Level 3 marketable security, which had no fair value at December 31, 2010 and 2009, and whose fair value was $0.1 million at December 31, 2008.#160;#160;This Level 3 security was valued using information provided by the Company#8217;s investment advisors and other sources, including quoted bid prices which took into consideration the securities#8217; lack of liquidity.#160;#160;During the years ended December 31, 2009 and 2008, the Company recorded charges of $0.1 million and $0.7 million, respectively, for other-than-temporary impairment of this Level 3 marketable security; therefore, as of December 31, 2009, the fair value of this security had been written down to zero.#160;#160;There were no purchases, sales, or maturities of Level 3 marketable securities and no unrealized gains or losses related to Level 3 marketable securities for the years ended December 31, 2010 and 2009.#160;#160;There were no transfers of marketable securities between Levels 1, 2, or 3 classifications during the years ended December 31, 2010 and 2009./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As described in Note 2 above under #8220;Use of Estimates#8221;, on a quarterly basis, the Company reviews its portfolio of marketable securities, using both quantitative and qualitative factors, to determine if declines in fair value below cost are other-than-temporary.#160;#160;With respect to debt securities, this review process also includes an evaluation of the Company#8217;s (a) intent to sell an individual debt security or (b) need to sell the debt security before its anticipated recovery or maturity.#160;#160;With respect to equity securities, this review process includes an evaluation of the Company#8217;s ability and intent to hold the securities until their full value can be recovered./font/div

Commitments and Contingencies	12 Months Ended
Commitments and Contingencies	Dec. 31, 2010
Notes to Financial Statements [Abstract]
Commitments and Contingencies	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"11.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Commitments and Contingencies/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"a. Leases/font/div gt;div style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Descriptions of Lease Agreements/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company leases laboratory and office facilities in Tarrytown, New York, under a December 2006 lease agreement, as amended (the #8220;Tarrytown Lease#8221;).#160;#160;The facilities leased by the Company under the Tarrytown Lease include (i) space in previously existing buildings, (ii) newly constructed space in two new buildings (#8220;Buildings A and B#8221;) that was complet ed during the third quarter of 2009 and, (iii) under a December 2009 amendment to the Tarrytown Lease, additional new space that is under construction in a third new building (#8220;Building C#8221;) and expected to be completed in the first quarter of 2011.#160;#160;The Tarrytown Lease will expire in June 2024 and contains three renewal options to extend the term of the lease by five years each, escalations at 2.5% per annum, and early termination options for various portions of the space exclusive of the newly constructed space in Buildings A and B.#160;#160;#160;The Tarrytown Lease provides for monthly payments over its term and additional charges for utilities, taxes, and operating expenses.#160;#160;Certain premises under the Tarrytown Lease are accounted for as operating leases.#160;#160;However, for Buildings A, B, and C that the Company is leasing, the Company is deemed, in substance, to be the owner of the landlord#8217;s buildings in accor dance with the application of FASB authoritative guidance, and the landlord#8217;s costs of constructing these new facilities are required to be capitalized on the Company#8217;s books as a non-cash transaction, offset by a corresponding lease obligation on the Company#8217;s balance sheet./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In connection with the Tarrytown Lease, at lease inception, the Company issued aa id="exp1" name="exp1"!--EFPlaceholder--/a letter of credit in the amount of $1.6 million to its landlord, which was collateralized by a $1.6 million bank certificate of deposit at December 31, 2009.a id="exp3" name="exp3"!--EFPlaceholder--/a#160;#160;During 2010, the Company increased t his letter of credit to $3.4 million, in accordance with the provisions of the Tarrytown Lease, and collateralized the letter of credit with cash and marketable debt securities totaling $3.6 million.#160;#160;Such collateral at December 31, 2010 and 2009 has been classified as restricted cash and marketable securities./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;In October 2008, the Company entered into a sublease with sanofi-aventis U.S. Inc. for office space in Bridgewater, New Jersey.#160;#160;The lease commenced in January 2009 and expires in July 2011. The Company also formerly leased additional office space in Tarrytown, New York under operating subleases that ended at various times through September 2009./font /divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company also leases certain laboratory and office equipment under operating and capital leases which expire at various times through 2013./font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/fontbr /#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Commitments under Operating Leases/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The estimated future minimum noncancelable lease commitments under operating leases were as follows:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"December 31,/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center" t;font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;Facilities/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160; mp;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;Equipment/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;# 160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;font style="DISPLAY: inline"Total/font/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2011/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$6,098/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 23pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; F ONT-FAMILY: times new roman"$225/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$6,323/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2012/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,468/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; T EXT-INDENT: 0pt; MARGIN-RIGHT: 23pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"118/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"5,586/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2013/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6,617/font/div/td td valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 23pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"24/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6,641/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2014/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DI SPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6,733/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6,733/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"2015/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FO NT-SIZE: 10pt; FONT-FAMILY: times new roman"6,866/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"6,866/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Thereafter/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"fon t style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"64,196/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 23pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"/font#160;/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"64,196/font/font/div/td/trtrtd valign="top" width="29%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/t dtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$95,978/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 23pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"$367/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"fon t style="DISPLAY: inline"$96,345/font/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Rent expense under operating leases was:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"Year Ending December 31,/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;Facilities/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;# 160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;font style="DISPLAY: inline"Equipment/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;Total/font/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left" font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2010/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$7,301/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$335/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$7,636/font/div/td/trtrtd valign="top" align="left" width="29%" gt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2009/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"7,722/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"395/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"8 ,117/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2008/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"6,530/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"416/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18. 5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"6,946/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In addition to its rent expense for various facilities, the Company paid rental charges for utilities, real estate taxes, and operating expenses of $10.3 million, $8.4 million, and $8.4 million for the years ended December 31, 2010, 2009, and 2008, respectively./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Com mitments under Capital Leases/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In 2010, the Company entered into capital leases in connection with acquisitions of new equipment.#160;#160;The lease obligations are collateralized with marketable debt securities totaling $3.5 million; such collateral has been classified as restricted cash and marketable securities at December 31, 2010./font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/fontbr /#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPL AY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The estimated future minimum noncancelable lease commitments under capital leases were as follows:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"December 31,/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;Equipment/font/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2011/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MAR GIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$1,137/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2012/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"1,135/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2013/font/div /tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"995/font/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Total minimum lease payments/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"3,267/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Less: amount representing interest/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"(438)/font/font/div/td/trtrtd valign="top" width="29%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font styl e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"$2,829/font/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"At the end of the lease term, the Company is required to purchase the leased equipment for a nominal amount defined in the lease agreement.#160;#160;At December 31, 2010, capital lease obligations totaling $2.8 million were included in other liabilities.#160;#160;There were no capital lease obligations at December 31, 2009.#160;#160;As of December 31, 2010, the Company had $0.7 million of financing available under a capital equipment lease line./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt" br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Facility Lease Obligations/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As described above, in connection with the application of FASB authoritative guidance to the Company#8217;s lease of office and laboratory facilities in Buildings A and B, the Company capitalized the landlord#8217;s costs of constructing the new facilities, which totaled $58.4 million as of December 31, 2010, and recognized a corresponding facility lease obligation of $58.4 million.#160;#160;The Company also recognized, as additional facility lease oblig ation, reimbursements totaling $56.9 million from the Company#8217;s landlord during 2010 and 2009 for tenant improvement costs that the Company incurred since, under FASB authoritative guidance, such payments that the Company receives from its landlord are deemed to be a financing obligation.#160;#160;#160;Monthly lease payments on these facilities are allocated between the land element of the lease (which is accounted for as an operating lease) and the facility lease obligation, based on the estimated relative fair values of the land and buildings.#160;#160;The imputed interest rate applicable to the facility lease obligation is approximately 11%.#160;#160;The new facilities were placed in service by the Company in September 2009.#160;#160;For the years ended December 31, 2010 and 2009, the Company recognized in its statement of operations $9.1 million and $2.3 million, respectively, of interest expense in connection with the facility lease obligation. #160;#160;At December 31, 2010 and 2009, the facility lease obligation balance in connection with Buildings A and B was $113.7 million and $81.0 million, respectively./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In addition, as described above, in December 2009, the Company amended its December 2006 agreement to lease additional new laboratory and office facilities in Building C that is under construction.#160;#160;In connection with the application of FASB authoritative guidance to the Company#8217;s lease of these additional new facilities, the Company is deemed, in substance, to be the owner of the landlord#8217;s building, and the landlord#8217;s costs of constructing Building C is required to be capitalized on the Company#8217;s books as a non-cash transaction, offset by a corresponding lease obligation on the Company#8217;s balance sheet.#160;#160;As of December 31, 2010, the Company capitalized $27.8 million of the landlord#8217;s costs of constructing Building C, and recognized a corresponding facility lease obligation of $27.8 million.#160;#160;The Company also recognized, as additional facility lease obligation, reimbursements totaling $14.2 million from the Company#8217;s landlord during 2010 for tenant improvement costs that the Company incurred since, under FASB authoritative guidance, such payments that the Company receives from its landlord are deemed to be a financing obligation.#160;#160;#160;Monthly lease payments on these facilities will commence in January 2011.#160;#160;Rent expense in connection with the land element of these additional facilities, which is accounted for as an operating lease, commenced in December 2009 and is recorded as a deferred liabil ity until lease payments commence in January 2011.#160;#160;In addition, interest expense is imputed at a rate of approximately 9%, and is capitalized and deferred in connection with this facility lease obligation.#160;#160;At December 31, 2010 and 2009, the facility lease obligation balance in connection with Building C was $46.4 million and $28.0 million, respectively./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The estimated future minimum noncancelable commitments under these facility lease obligations, as of December 31, 2010, were as follows:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd style="BORDER-BOT TOM: black 2px solid" valign="top" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"December 31,/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;Buildings A and B/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align=" center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;Building C/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;Total/font/font/div/td/trtrtd valign="top" alig n="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2011/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$11,347/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$2,468/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA MILY: Times New Roman"$13,815/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2012/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"12,603/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2,767/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TE XT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"15,370/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2013/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"12,843/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"4,285/font/div /tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"17,128/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2014/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"13,090/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right" t;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"4,403/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"17,493/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2015/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"13,343/font/div/tdtd valign="top" align="right" width="14%" gt;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"4,524/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"17,867/font/div/td/trtrtd valign="top" align="left" width="29%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Thereafter/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font styl e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"124,515/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"43,783/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"168,298/font/font/div/td/trtrtd valign="top" width="29%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"$187,741/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"$62,230/font/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 27.5pt" align="right"font style="DISPLAY: inline; FONT - -SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"$249,971/font/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"b. Research Collaboration and Licensing Agreements/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As part of the Company's research and development efforts, the Company enters into research collaboration and licensing agreemen ts with related and unrelated companies, scientific collaborators, universities, and consultants.#160;#160;These agreements contain varying terms and provisions which include fees and milestones to be paid by the Company, services to be provided, and ownership rights to certain proprietary technology developed under the agreements.#160;#160;Some of the agreements contain provisions which require the Company to pay royalties, as defined, at rates that range from 0.25% to 16.5%, in the event the Company sells or licenses any proprietary products developed under the respective agreements./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Certain agreements under which the Company is required to pay fees permit the Company, upon 30 to 90-day written notice, to terminate such agreements.#160;#160;With respect to payments associated with these agreements, the Company incurred expenses of $1.6 million, $2.8 million, and $3.5 million for the years ended December 31, 2010, 2009, and 2008, respectively./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In connection with the Company#8217;s receipt of marketing approval from the FDA for ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-FAMILY: Symbol, serif"#210;/font for the treatment of CAPS, in 2008, the Company commenced paying royalties under various licensing agreements based on ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font net product sales. ;#160;#160;For the years ended December 31, 2010, 2009, and 2008, ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font royalties totaled $1.7 million, $1.5 million, and $0.6 million, respectively, and are included in cost of goods sold./font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/fontbr /#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In July 2008, the Company and Cellectis S.A. (#8220;Cellectis#8221;) entered into an Amended and Restated Non-Exclusive License Agreement (the #8220;Cellectis Agreement#8221;).#160;#160;The Cellectis Agreement resolved a dispute between the part ies related to the interpretation of a license agreement entered into by the parties in December 2003 pursuant to which the Company licensed certain patents and patent applications from Cellectis.#160;#160;Pursuant to the Cellectis Agreement, in July 2008, the Company made a non-refundable $12.5 million payment to Cellectis (the #8220;Cellectis Payment#8221;) and agreed to pay Cellectis a low single-digit royalty based on revenue received by the Company from any future licenses or sales of the Company#8217;s font style="DISPLAY: inline; FONT-STYLE: italic"VelociGene/fontfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font or font style="DISPLAY: inline; FONT-STYLE: italic"VelocImmune/fontfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font products and services.#160;#160;No royalties are payable to Cellectis with respect to the Company#8217; s font style="DISPLAY: inline; FONT-STYLE: italic"VelocImmune/fontfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font license agreements with AstraZeneca and Astellas or the Company#8217;s antibody collaboration with sanofi-aventis.#160;#160;Moreover, no royalties are payable to Cellectis on any revenue from commercial sales of antibodies from the Company#8217;s font style="DISPLAY: inline; FONT-STYLE: italic"VelocImmune/fontfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font technology./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company began amortizing the Cellectis Payment in the second quarter of 2008 in propo rtion to past and future anticipated revenues under the Company#8217;s license agreements with AstraZeneca and Astellas and the Discovery and Preclinical Development Agreement under the Company#8217;s antibody collaboration with sanofi-aventis (as amended in November 2009).#160;#160;In 2010, 2009, and 2008, the Company recognized $0.9 million, $2.3 million, and $2.7 million, respectively, of expense in connection with the Cellectis Payment.#160;#160;At December 31, 2010 and 2009, the unamortized balance of the Cellectis Payment, which was included in other assets, was $6.6 million and $7.6 million, respectively.#160;#160;The Company estimates that it will recognize expense of $1.0 million in each of 2011, 2012, and 2013, and $0.9 million in each of 2014 and 2015, in connection with the Cellectis Payment./font/div

long-Term Incentive Plans	12 Months Ended
long-Term Incentive Plans	Dec. 31, 2010
Notes to Financial Statements [Abstract]
Long-Term Incentive Plans	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"13.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Long-Term Incentive Plans/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"During 2000, the Company established the Regeneron Pharm aceuticals, Inc. 2000 Long-Term Incentive Plan which, as amended and restated (the #8220;2000 Incentive Plan#8221;), provides for the issuance of up to 29,307,016 shares of Common Stock in respect of awards.#160;#160;Employees of the Company, including officers, and nonemployees, including consultants and nonemployee members of the Company#8217;s board of directors, (collectively, #8220;Participants#8221;) may receive awards as determined by a committee of independent directors (#8220;Committee#8221;).#160;#160;The awards that may be made under the 2000 Incentive Plan include: (a) Incentive Stock Options (#8220;ISOs#8221;) and Nonqualified Stock Options, (b) shares of Restricted Stock, (c) shares of Phantom Stock, (d) Stock Bonuses, and (e) Other Awards./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align= "justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Stock Option awards grant Participants the right to purchase shares of Common Stock at prices determined by the Committee; however, in the case of an ISO, the option exercise price will not be less than the fair market value of a share of Common Stock on the date the Option is granted.#160;#160;Options vest over a period of time determined by the Committee, generally on a pro rata basis over a three to five year period.#160;#160;The Committee also determines the expiration date of each Option; however, no ISO is exercisable more than ten years after the date of grant.#160;#160;The maximum term of options that have been awarded under the 2000 Incentive Plan is ten years./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font sty le="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Restricted Stock awards grant Participants shares of restricted Common Stock or allow Participants to purchase such shares at a price determined by the Committee.#160;#160;Such shares are nontransferable for a period determined by the Committee (#8220;vesting period#8221;).#160;#160;Should employment terminate, as defined by the 2000 Incentive Plan, the ownership of the Restricted Stock, which has not vested, will be transferred to the Company, except under defined circumstances with Committee approval, in consideration of amounts, if any, paid by the Participant to acquire such shares.#160;#160;In addition, if the Company requires a return of the Restricted Shares, it also has the right to require a return of all dividends paid on such shares./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-IND ENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Phantom Stock awards provide the Participant the right to receive, within 30 days of the date on which the share vests, an amount, in cash and/or shares of the Company#8217;s Common Stock as determined by the Committee, equal to the sum of the fair market value of a share of Common Stock on the date such share of Phantom Stock vests and the aggregate amount of cash dividends paid with respect to a share of Common Stock during the period from the grant date of the share of Phantom Stock to the date on which the share vests.#160;#160;Stock Bonus awards are bonuses payable in shares of Common Stock which are granted at the discretion of the Committee./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font styl e="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Other Awards are other forms of awards which are valued based on the Company#8217;s Common Stock.#160;#160;Subject to the provisions of the 2000 Incentive Plan, the terms and provisions of such Other Awards are determined solely on the authority of the Committee./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The 2000 Incentive Plan contains provisions that allow for the Committee to provide for the immediate vesting of awards upon a change in control of the Company, as defined in the plan./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justif y"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As of December 31, 2010, there were 434,564 shares available for future grants under the 2000 Incentive Plan./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"During 1990, the Company established the 1990 Incentive Plan which, as amended, provided for a maximum of 6,900,000 shares of Common Stock in respect of awards.#160;#160;Employees of the Company, including officers, and nonemployees, including consultants and nonemployee members of the Company#8217;s board of directors, received awards as determined by a committee of independent directors.#160;#160;Under the provisions of the 1990 Incentive Plan, there will be no future awards from the plan.#160; ;#160;Awards under the 1990 Incentive Plan consisted of Incentive Stock Options and Nonqualified Stock Options which generally vested on a pro rata basis over a three or five year period and had a term of ten years./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%" align="center" border="0"tr valign="top"td style="WIDTH: 4.5pt"divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/div/tdtd style="WIDTH: 18pt"div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"a./font/div/tdtddiv align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Stock Options/font/di v/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Transactions involving stock option awards during 2010 under the 1990 and 2000 Incentive Plans are summarized in the table below./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="36%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: bl ock; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"Stock Options:/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIG HT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Number of font style="DISPLAY: inline"Shares/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Weighted-Average/font/divdiv s tyle="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"Exercise Price/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt ; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Weighted-Average Remaining Contractual Term (in font style="DISPLAY: inline"years)/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARG IN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Intrinsic Value (in font style="DISPLAY: inline"thousands)/font/font/div/td/trtrtd valign="top" align="left" width="36%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Outstanding at December 31, 2009/ font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"21,788,755/font/div/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$18.45/font/div/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" width="36%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Ti mes New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" align="left" width="36%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline; FONT-WEIGHT: bold"2010:/font#160;#160;#160;G ranted/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"4,319,856/font/div/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$29.43/font/div/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" align="left" width="36%"div style="DISPLAY: block; MARGIN-LEFT : 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;Forfeited/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"(183,252)/font/div/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$20.22/font/div/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font ;/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" align="left" width="36%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;Expired/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"(887,281)/font/div/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="ri ght"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$38.63/font/div/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" align="left" width="36%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;Exercised/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;(1,675,830)/font/font/div/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$15.24/font/div/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" align="left" width="36%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT - -SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;Outstanding at December 31, 2010/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"23,362,248/font/font/div/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$19.93/font/div/tdtd valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RI GHT: 18.55pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"6.47/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$308,766/font/div/td/trtrtd valign="top" width="36%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times Ne w Roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" align="left" width="36%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Vested and expected to vest at December 31, 2010/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"22,803,097/font/div/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 1 0pt; FONT-FAMILY: Times New Roman"$19.81/font/div/tdtd valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.55pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"6.38/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$304,116/font/div/td/trtrtd valign="top" width="36%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="13%"font style="DIS PLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="10%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" align="left" width="36%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Exercisable at December 31, 2010/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"12,910,390/font/div/tdtd valig n="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$17.54/font/div/tdtd valign="top" align="right" width="10%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 18.55pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"4.91/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 14.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$201,662/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT : 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="MARGIN-LEFT: 18pt"/fontThe Company satisfies stock option exercises with newly issued shares of the Company#8217;s Common Stock.#160;#160;The total intrinsic value of stock options exercised during 2010, 2009, and 2008 was $21.4 million, $13.2 million, and $11.9 million,#160;#160;#160;#160;respectively.#160;#160;The intrinsic value represents the amount by which the market price of the underlying stock exceeds the exercise price of an option./font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/fontbr /#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inli ne; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company grants stock options with exercise prices that are equal to or greater than the average market price of the Company#8217;s Common Stock on the date of grant (#8220;Market Price#8221;).#160;#160;The table below summarizes the weighted-average exercise prices and weighted-average grant-date fair values of options issued during the years ended December 31, 2010, 2009, and 2008.#160;#160;The fair value of each option granted under the 2000 Incentive Plan during 2010, 2009, and 2008 was estimated on the date of grant using the Black-Scholes option-pricing model./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd valign="top" width="32%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd style="BORDER-BOTTO M: black 2px solid" valign="top" width="15%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Number of font style="DISPLAY: inline"Options Granted/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Weighted-Average Exercise font style="DISPLAY: inline"Pr ice/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Weighted-Average Fair font style="DISPLAY: inline"Value/font/font/div/td/trtrtd valign="top" width="32%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2010:/font/div/tdtd valign="top" width="15%" ;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="14%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" width="32%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;Exercise price equal to Market Price/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"4,319,856/ font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$29.43/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$13.36/font/div/td/trtrtd valign="top" width="32%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="15%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="14%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times N ew Roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" width="32%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2009:/font/div/tdtd valign="top" width="15%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="14%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" width="32%" ;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;Exercise price equal to Market Price/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"3,490,560/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$20.69/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DI SPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$10.89/font/div/td/trtrtd valign="top" width="32%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="15%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="14%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" width="32%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2008:/font t;/div/tdtd valign="top" width="15%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="14%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" width="32%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;Exercise price equal to Market Price/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE : 10pt; FONT-FAMILY: Times New Roman"4,126,600/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$17.38/font/div/tdtd valign="top" align="right" width="11%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$8.45/font/div/td/trtrtd valign="top" width="32%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="15%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="14%"font style=" DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="11%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"For the years ended December 31, 2010, 2009, and 2008, $29.4 million, $27.4 million, and $30.3 million, respectively, of non-cash stock-based compensation expense related to non-performance based stock option awards was recognized in operating expenses.#160;#160;As of December 31, 2010, there was $57.5 million of stock-based compensation cost related to outstanding non-performance based stock options, net of estimated forfeitures, which had not yet bee n recognized in operating expenses.#160;#160;The Company expects to recognize this compensation cost over a weighted-average period of 1.8 years./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In addition, there were 2,486,510 performance-based options which were unvested as of December 31, 2010 of which, subject to the optionee satisfying certain service conditions, 664,760 options that were issued in 2005 would vest upon achieving certain defined sales targets for the Company#8217;s products and 1,821,750 options that were issued in 2008, 2009, and 2010 would vest upon achieving certain development milestones for the Company#8217;s product candidates.#160;#160;In light of the status of the Company#8217;s development programs at Decemb er 31, 2010, the Company estimates that all of the performance-based options issued in 2008, 2009, and 2010 will vest since the Company considers these options#8217; performance conditions to be probable of attainment.#160;#160;Principally as a result, in 2010, the Company recognized $8.1 million of non-cash stock-based compensation expense related to these performance options.#160;#160;In light of the status of the Company#8217;s development programs at December 31, 2009, the Company estimated that approximately two-thirds of the performance-based options issued in 2008 and 2009 would vest; therefore, in 2009, the Company recognized $1.7 million of non-cash stock-based compensation expense, related to these performance-based options.#160;#160;As of December 31, 2010, there was $17.6 million of stock-based compensation cost which had not yet been recognized in operating expenses related to the performance-based options that the Company currently estimates will vest. p;#160;#160;#160;The Company expects to recognize this compensation cost over a weighted-average period of 2 years.#160;#160;In addition, potential compensation cost of $2.5 million related to the performance options issued in 2005, whose performance conditions (based on current facts and circumstances) are not currently considered by the Company to be probable of attainment, will begin to be recognized only if, and when, the Company estimates that it is probable that these options will vest.#160;#160;The Company#8217;s estimates of the number of performance-based options that will vest will be revised, if necessary, in subsequent periods.#160;#160;Changes in these estimates may materially affect the amount of stock-based compensation recognized in future periods related to performance-based options./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline; TEXT-DECORATION: underline"Fair value Assumptions:/font/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The following table summarizes the weighted average values of the assumptions used in computing the fair value of option grants during 2010, 2009, and 2008./font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/fontbr /#160;/divdivtable cellspacing="0" cellpadding="0" width="100%"trtd valign="t op" width="26%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160; 2010/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 27p t; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160; 2009/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="left" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#1 60;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160; 2008/font/font/div/td/trtrtd valign="top" width="26%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Expected volatility/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"47%/font/div/tdtd valign="top " align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"54%/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"53%/font/div/td/trtrtd valign="top" align="left" width="26%"div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Expected lives from grant date/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"fon t style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"5.6 years/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"5.9 years/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;5.5 years/font/div/td/trtrtd valign="top" width="26%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Expected dividend yield/font/div/tdtd val ign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"0%/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"0%/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"0%/font/div/td/trtrtd valign="top" width="26%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SI ZE: 10pt; FONT-FAMILY: Times New Roman"Risk-free interest rate/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2.11%/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"2.87%/font/div/tdtd valign="top" align="right" width="15%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"1.73%/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Expected volatility has been estimated based on actual movements in the Company#8217;s stock price over the most recent historical periods equivalent to the options#8217; expected lives.#160;#160;Expected lives are principally based on the Company#8217;s historical exercise experience with previously issued employee and board of directors option grants.#160;#160;The expected dividend yield is zero as the Company has never paid dividends and does not currently anticipate paying any in the foreseeable future.#160;#160;The risk-free interest rates are based on quoted U.S. Treasury rates for securities with maturities approximating the options#8217; expected lives./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%" align="center" border="0"tr valign="top"td style="WIDTH: 4.5pt"divfont style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/div/tdtd style="WIDTH: 18pt"div style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"b./font/div/tdtddiv align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-STYLE: italic; FONT-FAMILY: Times New Roman"Restricted Stock/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMIL Y: Times New Roman"A summary of the Company#8217;s activity related to Restricted Stock awards for the year ended December 31, 2010 is summarized below:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="41%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"Restricted Stock:/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"div style="DISPLAY : block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Number of font style="DISPLAY: inline"Shares/font/font/div/tdtd valign="top" width="2%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DIS PLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Weighted-Average/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Grant Date Fair font style="DISPLAY: inline"Value/font/font/div/td/trtrtd valign="top" align="left" width="41%"div style="DISPLAY: block; MARGI N-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Outstanding at December 31, 2009/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"500,000/font/div/tdtd valign="top" width="2%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$21.92/font/div/td/trtrtd valign="top" width="41%"font style="DISPLAY: inline; FON T-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="2%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="14%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" align="left" width="41%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline; FONT-WEIGHT: bold"2010:/font#160;#160;#160;Granted/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" align="right" width="12% "div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"345,000/font/font/div/tdtd valign="top" width="2%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$30.37/font/div/td/trtrtd valign="top" align="left" width="41%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;#160;#160; #160;#160;#160;#160;#160;#160;#160;#160;Outstanding at December 31, 2010/font/div/tdtd style="BORDER-BOTTOM: black 4px double" valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 5.05pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"845,000/font/font/div/tdtd valign="top" width="2%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 29.65pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$25.37/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT - -INDENT: 0pt"br //divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company recognized non-cash stock-based employee compensation expense from Restricted Stock awards of $2.4 million, $2.2 million, and $2.2 million in 2010, 2009, and 2008, respectively.#160;#160;As of December 31, 2010, there were 845,000 unvested shares of Restricted Stock outstanding and $14.6 million of stock-based compensation cost related to these unvested shares which had not yet been recognized in operating expenses.#160;#160;The Company expects to recognize this compensation cost over a weighted-average period of 2.4 years./font/div

Income Taxes	12 Months Ended
Income Taxes	Dec. 31, 2010
Notes to Financial Statements [Abstract]
Income Taxes	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"16.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Income Taxes/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"For the year ended December 31, 2010, the Company incurred a net loss for tax purposes and recognized a full valuation allowance against deferred taxes.#160;#160;Accordingly, no provision or benefit for income taxes was recorded in 2010./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"For the year ended December 31, 2009, the Company incurred a net loss for tax purposes and recognized a full valuation allowance against deferred taxes.#160;#160;In 2009, the Company recognized a $4.1 million income tax benefit, consisting of (i) $2.7 million resulting from a provision in the Worker, Homeownership, and Business Assistance Act of 2009 that allows the Company to claim a refund of U.S. federal alternative minimum tax (#8220;AMT#8221;) that the Company paid in connection with its 2007 U.S. federal income tax return, as described below, (ii) $0.7 milli on income tax benefit resulting from a provision in the American Recovery and Reinvestment Act of 2009 that allows the Company to claim a refund for a portion of its unused pre-2006 research tax credits on its 2009 U.S. federal income tax return, and (iii) $0.7 million income tax benefit in connection with the net tax effect of the Company#8217;s unrealized gain on #8220;available-for-sale#8221; marketable securities, which is included in other comprehensive income in 2009./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"For the year ended December 31, 2008, the Company incurred a net loss for tax purposes and recognized a full valuation allowance against deferred taxes.#160;#160;During 2008, the Company implemented a tax planning strategy to util ize net operating loss carry-forwards (which were otherwise due to expire in 2008 through 2012) on its 2007 U.S. federal and New York State income tax returns that were filed in September 2008.#160;#160;The tax planning strategy included electing, for tax purposes only, to capitalize $142.1 million of 2007 research and development (#8220;Ramp;D#8221;) costs and amortize these costs over ten years for tax purposes.#160;#160;By capitalizing these Ramp;D costs, the Company was able to generate taxable income for tax year 2007 and utilize the net operating loss carry-forwards to offset this taxable income.#160;#160;As a result, the Company incurred and paid income tax expense of $3.1 million in 2008, which related to U.S. federal and New York State AMT and included $0.2 million of interest and penalties.#160;#160;This expense was partly offset by the Company#8217;s recognition of a $0.7 million income tax benefit in 2008, resulting from a provision in the Housing Assistance Tax Act of 2008 that allowed the Company to claim a refund for a portion of its unused pre-2006 research tax credits on its 2008 U.S federal income tax return./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The tax effect of temporary differences, net operating loss carry-forwards, and research and experimental and other tax credit carry-forwards as of December 31, 2010 and 2009 is as follows:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv align="left"table cellspacing="0" cellpadding="0" width="100%"trtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font /tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2010/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160 ;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: center" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt; TEXT-ALIGN: center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2009/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Deferred tax assets:/font/div/tdtd valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMIL Y: times new roman"#160;/font/tdtd valign="bottom" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd valign="bottom" colspan="2"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Net operating loss carry-forward/font/div/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"243,893/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: tim es new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"200,266/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Fixed assets/font/div/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times ne w roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"13,600/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%" font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"13,833/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Deferred revenue/font/div/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%" gt;font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"70,443/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"73,865/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/ font/td/trtrtd valign="bottom" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Deferred compensation/font/div/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"39,120/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" p;#160;/font/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"29,736/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Research and e xperimental and other tax credit carry-forwards/font/div/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"45,588/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: le ft" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"22,377/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Capitalized research and development costs/font/div/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/t dtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"38,865/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 1 0pt; FONT-FAMILY: times new roman"49,107/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Other/font/div/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"10,863/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"10,142/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd style ="PADDING-BOTTOM: 2px" valign="bottom" width="76%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Valuation allowance/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(462,372/font/font/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" v align="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: center" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"(399,326/font/font/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman")/font t;/td/trtrtd style="PADDING-BOTTOM: 4px" valign="bottom" width="76%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"--/font/font/tdtd style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt ; FONT-FAMILY: times new roman"#160;/font/tdtd style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"--/font/font/tdtd style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/tr/table/divdiv style="DISPLAY: block; TEXT-IND ENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company#8217;s valuation allowance increased by $63.0 million in 2010, due primarily to increases in the net operating loss carry-forward and tax credit carry-forwards.#160;#160;In 2009, the Company#8217;s valuation allowance increased by $19.0 million, due primarily to the increase in the net operating loss carry-forward./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company is primarily subject to U.S. federal and New York State income tax. The difference between the Company#8217;s effective income tax rate and th e U.S federal statutory rate of 35% is primarily attributable to an increase in the deferred tax valuation allowance.#160;#160;Due to the Company#8217;s history of losses, all tax years remain open to examination by U.S. federal and state tax authorities.#160;#160;In January 2011, U.S. federal tax authorities commenced an examination of the Company#8217;s 2007 and 2008 U.S. federal income tax returns./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As of December 31, 2010 and 2009, the Company had no accruals for interest or penalties related to income tax matters./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT : 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"As of December 31, 2010, the Company had available for tax purposes unused net operating loss carry-forwards of $614.9 million which will expire in various years from 2018 to 2030 and included $7.1 million of net operating loss carry-forwards related to exercises of Nonqualified Stock Options and disqualifying dispositions of Incentive Stock Options, the tax benefit from which, if realized, will be credited to additional paid-in capital. The Company's research and experimental and other tax credit carry-forwards expire in various years from 2011 to 2030.#160;#160;Under the Internal Revenue Code and similar state provisions, substantial changes in the Company#8217;s ownership have resulted in an annual limitation on the amount of net operating loss and tax credit carry-forwards that can be utilized in future years to offset future taxable income.#160;#160;This annual limitation may result in the expiration of net operating losses and tax credit carry-forwards before utilization./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The following table summarizes the gross amounts of unrecognized tax benefits at the beginning and end of 2010:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv align="left"table cellspacing="0" cellpadding="0" width="100%"trtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160; /font/tdtd style="PADDING-BOTTOM: 2px" valign="bottom"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman" t;#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="bottom" colspan="2"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: -36pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"2010/font/font/div/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="88%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Balance as of January 1/font/div/tdtd valign="bottom" align="right" width="1%"font style="DIS PLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"-/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd valign="bottom" align="left" width="88%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Gross increases related to current year tax positions/font/div/tdtd valign="bottom" align="right" wid th="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"3,550/font/tdtd style="TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd style="PADDING-BOTTOM: 2px" valign="bottom" align="left" width="88%"div style="DISPLAY: block; MARGIN-LEFT: 27pt; TEXT-INDENT: -27pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Gross increases related to prior year tax positions/fo nt/div/tdtd style="PADDING-BOTTOM: 2px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 2px solid; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"9,269/font/font/tdtd style="PADDING-BOTTOM: 2px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/trtrtd style="PADDING-BOTTOM: 4px" valign="bottom" align="left" width="88%"div style=" DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"Balance as of December 31/font/div/tdtd style="PADDING-BOTTOM: 4px" valign="bottom" align="right" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: left" valign="bottom" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"$/font/tdtd style="BORDER-BOTTOM: black 4px double; TEXT-ALIGN: right" valign="bottom" width="9%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"font style="DISPLAY: inline"12,819/font/font/tdtd style="PADDING-BOTTOM: 4px; TEXT-ALIGN: left" valign="bottom" nowrap="nowrap" width="1%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: times new roman"#160;/font/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In 2010, the gross increases in unrecognized tax benefits related to prior year tax positions was primarily due to the Company#8217;s calculations of certain pre-2010 tax credits.#160;#160;Due to the amounts of the Company#8217;s net operating loss carry-forward and tax credit carry-forwards, the Company has not accrued interest or penalties related to these unrecognized tax benefits.#160;#160;In addition, unrecognized tax benefits at December 31, 2010, if recognized, would not affect the Company#8217;s effective tax rate since the adjustments to deferred tax assets would be fully offset by adju stments to the Company#8217;s valuation allowance.#160;#160;For the years ended December 31, 2009 and 2008, income tax positions that were deemed uncertain under the recognition thresholds and measurement attributes prescribed in FASB authoritative guidance were not significant./font/div

BALANCE SHEETS (Parenthetical) - USD ($)	Dec. 31, 2010	Dec. 31, 2009
Stockholders' equity
Preferred stock, par value	$ 0.01	$ 0.01
Preferred stock, authorized	30,000,000	30,000,000
Preferred stock, outstanding	0	0
Common Stock, issued	87,238,301	78,860,862
Common Stock, outstanding	87,238,301	78,860,862
Class A [Member]
Stockholders' equity
Common Stock, issued	2,182,036	2,244,698
Common Stock, outstanding	2,182,036	2,244,698

STATEMENTS OF OPERATIONS - USD ($)	12 Months Ended
STATEMENTS OF OPERATIONS - USD ($)	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Revenues
Sanofi-aventis collaboration revenue	$ 311,332,000	$ 247,140,000	$ 153,972,000
Other collaboration revenue	75,393,000	67,317,000	31,166,000
Technology licensing	40,150,000	40,013,000	40,000,000
Net product sales	25,254,000	18,364,000	6,249,000
Contract research and other	6,945,000	6,434,000	7,070,000
Total Revenues	459,074,000	379,268,000	238,457,000
Expenses
Research and development	489,252,000	398,762,000	274,903,000
Selling, general, and administrative	65,201,000	52,923,000	48,880,000
Cost of goods sold	2,093,000	1,686,000	923,000
Total Expenses	556,546,000	453,371,000	324,706,000
Loss from operations	(97,472,000)	(74,103,000)	(86,249,000)
Other income (expense)
Investment income	2,122,000	4,488,000	18,161,000
Total Other Income (Expense)	(6,996,000)	2,151,000	9,471,000
Net loss per share, basic and diluted	$ (1.26)	$ (0.85)	$ (1.00)

STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Statement [Line Items]
Beginning Balance	$ 396,762	$ 421,514	$ 459,348
Issuance of Common Stock in a public offering, net of issuance costs	174,828
Issuance of Common Stock in connection with exercise of stock options, net of shares tendered	21,464	9,270	7,949
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution	2,867	1,391	1,107
Stock-based compensation expense	39,897	31,259	32,523
Change in net unrealized gain (loss) on marketable securities	(3,535)	1,158	(284)
Ending Balance	$ 527,815	$ 396,762	$ 421,514
Common Stock [Member]
Statement [Line Items]
Beginning Balance (in shares)	78,861	77,642	76,592
Beginning Balance	$ 79	$ 78	$ 77
Issuance of Common Stock in a public offering, net of issuance costs (in shares)	6,325
Issuance of Common Stock in a public offering, net of issuance costs	$ 6
Issuance of Common Stock in connection with exercise of stock options, net of shares tendered (in shares)	1,533	1,134	980
Issuance of Common Stock in connection with exercise of stock options, net of shares tendered	$ 2	$ 1	$ 1
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution (in shares)	111	81	59
Issuance of Restricted Common Stock under Long-Term Incentive Plan (in shares)	345
Conversion of Class A Stock to Common Stock (in shares)	63	4	11
Ending Balance (in shares)	87,238	78,861	77,642
Ending Balance	$ 87	$ 79	$ 78
Additional Paid-in Capital [Member]
Statement [Line Items]
Beginning Balance	1,336,732	1,294,813	1,253,235
Issuance of Common Stock in a public offering, net of issuance costs	174,822
Issuance of Common Stock in connection with exercise of stock options, net of shares tendered	21,462	9,269	7,948
Issuance of Common Stock in connection with Company 401(k) Savings Plan contribution	2,867	1,391	1,107
Stock-based compensation expense	39,897	31,259	32,523
Ending Balance	1,575,780	1,336,732	1,294,813
Accumulated Deficit [Member]
Statement [Line Items]
Beginning Balance	(941,095)	(873,265)	(794,136)
Ending Balance	(1,045,563)	(941,095)	(873,265)
Accumulated Other Comprehensive Income (Loss) [Member]
Statement [Line Items]
Beginning Balance	1,044	(114)	170
Change in net unrealized gain (loss) on marketable securities	(3,535)	1,158	(284)
Ending Balance	(2,491)	1,044	(114)
Comprehensive Loss [Member]
Statement [Line Items]
Beginning Balance	(66,672)	(79,413)
Change in net unrealized gain (loss) on marketable securities	(3,535)	1,158	(284)
Ending Balance	$ (108,003)	$ (66,672)	$ (79,413)

STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	12 Months Ended
STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	Dec. 31, 2010	Dec. 31, 2009	Dec. 31, 2008
Adjustments to reconcile net loss to net cash provided by (used in) operating activities
Non-cash compensation expense	$ 39,897	$ 31,259	$ 32,523
Net realized loss (gain) on marketable securities	293	(56)	1,310
Changes in assets and liabilities
Increase in accounts receivable	(27,544)	(30,356)	(16,892)
Decrease (increase) in prepaid expenses and other assets	2,723	(4,574)	(6,560)
Net cash provided by (used in) operating activities	96,344	(72,230)	(89,086)
Cash flows from investing activities
Purchases of marketable securities	(605,124)	(199,997)	(581,139)
Sales or maturities of marketable securities	276,601	297,411	646,861
Purchases of restricted marketable securities	(7,063)	0	0
Decrease (increase) in restricted cash	1,122	50	(50)
Net cash (used in) provided by investing activities	(434,153)	146	30,815
Cash flows from financing activities
Repurchases or repayment of notes payable	0	0	(200,807)
Proceeds in connection with facility lease obligation	47,544	23,640	0
Payments in connection with facility lease obligation	(924)	(875)	0
Net proceeds from the issuance of Common Stock	196,790	8,598	7,949
Payments in connection with capital lease obligation	(104)	0	0
Net cash provided by (used in) financing activities	243,306	31,363	(192,858)
Net decrease in cash and cash equivalents	(94,503)	(40,721)	(251,129)
Cash and cash equivalents at beginning of period	207,075	247,796	498,925
Cash and cash equivalents at end of period	112,572	207,075	247,796
Supplemental disclosure of cash flow information
Cash paid for interest	12,737	2,525	9,348
Cash paid for income taxes	$ 0	$ 0	$ 3,079

Organization and Business	12 Months Ended
Organization and Business	Dec. 31, 2010
Notes to Financial Statements [Abstract]
Organization and Business	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"1.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Organization and Business/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Regeneron Pharmaceuticals, Inc. (the p;#8220;Company#8221; or #8220;Regeneron#8221;) was incorporated in January 1988 in the State of New York.#160;#160;The Company is engaged in the research, development, and commercialization of pharmaceutical products for the treatment of serious medical conditions.#160;#160;In 2008, the Company received marketing approval from the U.S. Food and Drug Administration (#8220;FDA#8221;) for the Company#8217;s first commercial drug product, ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-FAMILY: Symbol, serif"#210;/font (rilonacept) Injection for Subcutaneous Use for the treatment of Cryopyrin-Associated Periodic Syndromes (#8220;CAPS#8221;).#160;#160;The Company's facilities are primarily located in New York.#160;#160;The Company#8217;s business is subject to certain risks including, but not limited to, uncertainties relating to conducting pharmaceutical research, obtainin g regulatory approvals, commercializing products, and obtaining and enforcing patents./font/div

Technology Licensing Agreement	12 Months Ended
Technology Licensing Agreement	Dec. 31, 2010
Notes to Financial Statements [Abstract]
Technology Licensing Agreements	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"4.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Technology Licensing Agreements/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In February 2007, the Company entered into a six-year, non-exclusive license agr eement with AstraZeneca UK Limited to allow AstraZeneca to utilize the Company#8217;s font style="DISPLAY: inline; FONT-STYLE: italic"VelocImmune/fontfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-FAMILY: Symbol, serif"#210;/font technology in its internal research programs to discover human monoclonal antibodies.#160;#160;Under the terms of the agreement, AstraZeneca made a $20.0 million annual, non-refundable payment to the Company in each of 2010, 2009, 2008, and 2007.#160;#160;Each annual payment was deferred and recognized as revenue ratably over approximately the ensuing twelve-month period.#160;#160;In November 2010, as permitted by the agreement, MedImmune Limited (as successor by novation from AstraZeneca) gave written notice of voluntary termination of the agreement, effective in February 2011, thereby canceling its obligation to make either of the final two annual payments.#160;#160;Regen eron remains entitled to receive mid-single digit royalties on any future sales of antibody products discovered by MedImmune/AstraZeneca using the font style="DISPLAY: inline; FONT-STYLE: italic"VelocImmune/fontfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font technology.#160;#160;In connection with the AstraZeneca license agreement, for each of the years ended December 31, 2010, 2009, and 2008, the Company recognized $20.0 million of technology licensing revenue.#160;#160;In addition, deferred revenue at December 31, 2010, 2009, and 2008 was $2.9 million./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In March 2007, the Company entered into a six-year, non-exclusive license agreement with Astellas Pharma Inc. to allow Astellas to utilize the Company#8217;s font style="DISPLAY: inline; FONT-STYLE: italic"VelocImmune/fontfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/fontfont style="DISPLAY: inline; FONT-STYLE: italic"#160;/fonttechnology in its internal research programs to discover human monoclonal antibodies.#160;#160;Under the terms of the agreement, Astellas made a $20.0 million annual, non-refundable payment to the Company in each of 2010, 2009, 2008, and 2007.#160;#160;In July 2010, the license agreement with Astellas was amended and extended through June 2023.#160;#160;Under the terms of the amended agreement, Astellas made a $165.0 million up-front payment to the Company in August 2010, which was deferred upon receipt and will be recognized as revenue ratably over the seven-year period beginning in mid-2011.#160;#160;In addition, Astellas will make a $130.0 million second payment to the Company in June 2018 unless the license agreement has been terminated prior to that date.#160;#160;Astellas has the right to terminate the agreement at any time by providing 90 days#8217; advance written notice.#160;#160;Under certain limited circumstances, such as a material breach of the agreement by the Company, Astellas may terminate the agreement and receive a refund of a portion of its up-front payment or, if such termination occurs after June 2018, a portion of its second payment, to the Company under the July 2010 amendment to the agreement.#160;#160;The Company is entitled to receive a mid-single-digit royalty on any future sales of antibody products discovered by Astellas using the Company#8217;s font style="DISPLAY: inline; FONT-STYLE: italic"VelocImmune/fontfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font technology.#160;#160;In connection wi th the Astellas license agreement, for each of the years ended December 31, 2010, 2009, and 2008, the Company recognized $20.0 million of technology licensing revenue.#160;#160;In addition, deferred revenue at December 31, 2010, 2009, and 2008 was $173.7 million, $8.7 million, and $8.7 million, respectively./font/div

ARCALYST (rilonacept) Product Revenue	12 Months Ended
ARCALYST (rilonacept) Product Revenue	Dec. 31, 2010
Notes to Financial Statements [Abstract]
ARCALYST (rilonacept) Product Revenue	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"5.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top; FONT-FAMILY: Symbol, serif"#210;/font Product Revenue/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10 pt; FONT-FAMILY: Times New Roman"In February 2008, the Company received marketing approval from the FDA for ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font Injection for Subcutaneous Use for the treatment of CAPS.#160;#160;The Company had limited historical return experience for ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font beginning with initial sales in 2008 through the end of 2009; therefore, ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font net product sales were deferred until the right of return no longer existed and rebates could be reasonably estimated.#160;#160;Effective in the first quarter of 2010, the Company determined that it had accumulated sufficient historical data to reasonably estimate both product returns and rebates of ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTIC AL-ALIGN: text-top"#174;/font.#160;#160;As a result, $4.8 million of previously deferred ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font net product sales were recognized as revenue in the first quarter of 2010.#160;#160;The effect of this change in estimate related to ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font net product sales revenue was to lower the Company#8217;s net loss per share by $0.06 in 2010./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font net product sales totaled $25.3 million, $18. 4 million, and $6.3 million for the years ended December 31, 2010, 2009, and 2008, respectively.#160;#160;ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174; /fontnet product sales during 2010 included $20.5 million of net product sales made during this period and $4.8 million of previously deferred net product sales, as described above.#160;#160;There was no deferred ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font net product sales revenue at December 31, 2010.#160;#160;At December 31, 2009, deferred ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font net product sales revenue was $4.8 million./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font st yle="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;Cost of goods sold related to ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font sales, which consisted primarily of royalties and other period costs, totaled $2.1 million, $1.7 million, and $0.9 million for the years ended December 31, 2010, 2009, and 2008, respectively.#160;#160;To date, ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font shipments to the Company#8217;s customers have primarily consisted of supplies of inventory manufactured and expensed as research and development costs prior to 2008; therefore, the costs of these supplies were not included in costs of goods sold.#160;#160;Inventories related to ARCALYSTfont style="DISPLAY: inline; FONT-SIZE: 70%; VERTICAL-ALIGN: text-top"#174;/font, which were included in prepaid expenses and other curre nt assets, consisted of $0.7 million of work-in-process and $0.1 million of finished goods at December 31, 2010, and $0.4 million of work-in-process at December 31, 2009./font/div

Executive Stock Purchase Plan	12 Months Ended
Executive Stock Purchase Plan	Dec. 31, 2010
Notes Financial Statements [Abstract]
Executive Stock Purchase Plan	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"14.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Executive Stock Purchase Plan/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In 1989, the Company adopted an Executive Stock Purchase Plan (the #8220;Plan amp;#8221;) under which 1,027,500 shares of Class A Stock were reserved for restricted stock awards.#160;#160;The Plan provides for the compensation committee of the board of directors to award employees, directors, consultants, and other individuals (#8220;Plan participants#8221;) who render service to the Company the right to purchase Class A Stock at a price set by the compensation committee.#160;#160;The Plan provides for the vesting of shares as determined by the compensation committee and, should the Company's relationship with a Plan participant terminate before all shares are vested, unvested shares will be repurchased by the Company at a price per share equal to the original amount paid by the Plan participant.#160;#160;During 1989 and 1990, a total of 983,254 shares were issued, all of which vested as of December 31, 1999.#160;#160;As of December 31, 2010, there were 44,246 shares available for future grants under the Plan./font/div /regn:ExecutivestockpurchasePlantextblock> us-gaap:AccountsPayableAndAccruedLiabilitiesDisclosureTextBlock>

Employee Savings Plan	12 Months Ended
Employee Savings Plan	Dec. 31, 2010
Notes to Financial Statements [Abstract]
Employee Savings Plan	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"15.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Employee Savings Plan/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"In 1993, the Company adopted the provisions of the Regeneron Pharmaceuticals, Inc. 401(k) Savings Plan (the #8220;Savings Plan#8221;).#160;#160;The terms of the Savings Plan provide for employees who have met defined service requirements to participate in the Savings Plan by electing to contribute to the Savings Plan a percentage of their compensation to be set aside to pay their future retirement benefits, as defined.#160;#160;The Savings Plan, as amended and restated, provides for the Company to make discretionary contributions (#8220;Contribution#8221;), as defined.#160;#160;The Company recognized $3.2 million, $2.6 million, and $1.5 million of Contribution expense in 2010, 2009, and 2008, respectively.#160;#160;At December 31, 2010 and 2009, accrued Contribution expense totaled $2.9 million and $2.6 million, respectively.#160;#160;During the first quarter of 2011 and 2010, the Company contributed 91,761 and 111,419 shares, respectively, of Common Stock to the Savings Plan in satisfaction of these obligations./font/div t;

Net Loss Per Share Data	12 Months Ended
Net Loss Per Share Data	Dec. 31, 2010
Notes to Financial Statements [Abstract]
Net Loss Per Share Data	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"18.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Net Loss Per Share Data/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company#8217;s basic net loss per share amounts have been computed by dividing net loss by the weighted average number of Common and Class A shares outstanding.#160;#160;Net loss per share is presented on a combined basis, inclusive of Common Stock and Class A Stock outstanding, as each class of stock has equivalent economic rights.#160;#160;In 2010, 2009, and 2008, the Company reported net losses; therefore, no common stock equivalents were included in the computation of diluted net loss per share since such inclusion would have been antidilutive.#160;#160;The calculations of basic and diluted net loss per share are as follows:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd valign="top" width="37%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="37%" colspan="3"div style="DISPLAY: b lock; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"December 31,/font/div/td/trtrtd valign="top" width="37%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160; 2010/font/font/div/td td style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;2009/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160; 2008/font/font/div/td/trtrtd valign="top" width="37%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" align="left" width="37%"div style="DISPLAY: block; MARGIN-LEFT: 0 pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;Net loss (Numerator)/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$(104,468)/font/div/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$(67,830)/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Ro man"$(79,129)/font/div/td/trtrtd valign="top" width="37%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" align="left" width="37%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -18pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;Weighted-average shares, in thousands (Denominator )/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"82,926/font/div/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"79,782/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"78,827/font/div/td/trtrtd valign="top" width="37%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" align="left" width="37%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="left"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Basic and diluted net loss per share/font/div gt;/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$(1.26)/font/div/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$(0.85)/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 12.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$(1.00)/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT - -INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Shares issuable upon the exercise of options and vesting of restricted stock awards, which have been excluded from the diluted per share amounts because their effect would have been antidilutive, include the following:/font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd valign="top" width="37%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MAR GIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"December 31,/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" width="37%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#1 60;#160;#160;#160;#160;#160;#160;#160;#160; 2010/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160; 2009/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align= "center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160;#160; 2008/font/font/div/td/trtrtd valign="top" width="37%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Options:/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" width="37%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;Weighted average number, in thousands/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"21,428/font/div/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"20,040/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"17,598/font/div/td/trtrtd valign="top" width="37%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;Weighted average exercise price/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$18.80/font/div/tdtd valign="top" align="right" width="13%"div sty le="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$17.66/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$17.31/font/div/td/trtrtd valign="top" width="37%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" width="37%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Restricted Stock:/font/div/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="13%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="12%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/td/trtrtd valign="top" width="37%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify" font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;Weighted average number, in thousands/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"526/font/div/tdtd valign="top" align="right" width="13%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"500/font/div/tdtd valign="top" align="right" width="12%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 17.1pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"500/font/div/td t;/tr/table/div

Statement of Cash Flows	12 Months Ended
Statement of Cash Flows	Dec. 31, 2010
Notes to Financial Statements [Abstract]
Statement of Cash Flows	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"19.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Statement of Cash Flows/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Supplemental disclosure of noncash investing and financing activities:/font t;/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Included in accounts payable and accrued expenses at December 31, 2010, 2009, and 2008 were $10.7 million, $9.8 million, and $7.0 million of accrued capital expenditures, respectively./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Included in accounts payable and accrued expenses at December 31, 2009, 2008, and 2007 were $2.6 million, $1.5 million, and $1.1 million, respectively, of accrued 401(k) Savings Plan contribution expense.#160;#160;During the first quarter of 2010, 2009, and 20 08, the Company contributed 111,419, 81,086, and 58,575 shares, respectively, of Common Stock to the 401(k) Savings Plan in satisfaction of these obligations./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Pursuant to the application of FASB authoritative guidance to the Company#8217;s lease of office and laboratory facilities in Tarrytown, New York (see Note 11a), the Company recognized a facility lease obligation of $0.2 million and $31.7 million during 2010 and 2009, respectively, in connection with capitalizing, on the Company#8217;s books, the landlord#8217;s costs of constructing new facilities that the Company has leased./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block ; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Included in facility lease obligations and property, plant, and equipment at December 31, 2010 was $3.7 million of capitalized and deferred interest for the year ended December 31, 2010, as the related facilities being leased by the Company are currently under construction and lease payments on these facilities do not commence until January 2011./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"The Company incurred capital lease obligations of $2.9 million during 2010 in connection with acquisitions of new equipment./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //div div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Included in other assets at December 31, 2010 and 2009 was $0.2 million and $0.7 million, respectively, due to the Company in connection with employee exercises of stock options in December 2010./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Included in marketable securities at December 31, 2010, 2009, and 2008 were $1.4 million, $0.6 million, and $1.7 million of accrued interest income, respectively./font/div

Unaudited Quarterly Result	12 Months Ended
Unaudited Quarterly Result	Dec. 31, 2010
Notes to Financial Statements [Abstract]
Unaudited Quarterly Results	divtable cellspacing="0" cellpadding="0" width="100%"tr valign="top"td style="WIDTH: 36pt" align="right"divfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"20.#160;#160;/font/div/tdtddiv style="MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Unaudited Quarterly Results/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 18pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Summarized quarterly financial data for the years ended December 31, 2010 and 2 009 are set forth in the following tables./font/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd valign="top" width="20%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"First Quarter/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Ended/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="c enter"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"March 31, 2010/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Second Quarter /font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Ended/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"June 30, 2010 lt;/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Third Quarter /font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"E/fontfont style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"nded/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"September 30, 2010/font/font/div/td td style="BORDER-BOTTOM: black 2px solid" valign="top" width="17%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Fourth Quarter/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Ended/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"December 31, 2010/font/font/div/td/trtrtd valign="top" width="20%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /f ont/tdtd valign="top" width="64%" colspan="4"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"(Unaudited)/font/div/td/trtrtd valign="top" width="20%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Revenues/font/div/tdtd valign="top" align="right" width="16%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;$103,534/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-R IGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$115,886/font/div/tdtd valign="top" align="right" width="16%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$105,979/font/div/tdtd valign="top" align="right" width="17%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$133,675/font/div/td/trtrtd valign="top" width="20%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Net loss/font/div/tdtd valign ="top" align="right" width="16%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;(30,522)/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;(25,474)/font/div/tdtd valign="top" align="right" width="16%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;(33,875)/font/div/tdtd valign="top" align="right" width="17%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MAR GIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;(14,597)/font/div/td/trtrtd valign="top" width="20%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Net loss per share, basic and diluted:/font/div/tdtd valign="top" align="right" width="16%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FA MILY: Times New Roman"#160;#160;#160;#160;$(0.38)/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;$(0.31)/font/div/tdtd valign="top" align="right" width="16%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;$(0.41)/font/div/tdtd valign="top" align="right" width="17%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLA Y: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;$(0.17)/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //divdivtable cellspacing="0" cellpadding="0" width="100%"trtd valign="top" width="20%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"First Quarter/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Ended/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"March 31, 2009/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Second Quarter Ended/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"June 30, 2009/font/font/ div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="16%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Third Quarter Ended/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"September 30, 2009/font/font/div/tdtd style="BORDER-BOTTOM: black 2px solid" valign="top" width="17%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Fourth Quarter/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT - -INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Ended/font/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"font style="DISPLAY: inline"December 31, 2009/font/font/div/td/trtrtd valign="top" width="20%"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160; /font/tdtd valign="top" width="64%" colspan="4"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="center"font style="DISPLAY: inline; FONT-WEIGHT: bold; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"(Unaudited)/font/div/td/trtrtd valign="top" width="20%" t;div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Revenues/font/div/tdtd valign="top" align="right" width="16%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;$74,981/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$90,032/font/div/tdtd valign="top" align="right" width="16%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Ti mes New Roman"$117,455/font/div/tdtd valign="top" align="right" width="17%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"$96,800/font/div/td/trtrtd valign="top" width="20%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Net loss/font/div/tdtd valign="top" align="right" width="16%"div style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;(15,388)/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; T EXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;(14,938)/font/div/tdtd valign="top" align="right" width="16%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;(1,015)/font/div/tdtd valign="top" align="right" width="17%"div style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;(36,489)/font/div/td/trtrtd valign="top" width="20%"div style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"/font#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 9pt; TEXT-INDENT: -9pt; MARGIN-RIGHT: 0pt" align="justify"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"Net loss per share, basic and diluted:/font/div/tdtd valign="top" align="right" width="16%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 18pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;#160;$(0.19)/font/div/tdtd valign="top" align="right" width="14%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE : 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;$(0.19)/font/div/tdtd valign="top" align="right" width="16%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;#160;$(0.01)/font/div/tdtd valign="top" align="right" width="17%"div style="DISPLAY: block; TEXT-INDENT: 0pt"#160;/divdiv style="DISPLAY: block; MARGIN-LEFT: 0pt; TEXT-INDENT: 0pt; MARGIN-RIGHT: 21.6pt" align="right"font style="DISPLAY: inline; FONT-SIZE: 10pt; FONT-FAMILY: Times New Roman"#160;#160;$(0.46)/font/div/td/tr/table/divdiv style="DISPLAY: block; TEXT-INDENT: 0pt"br //div

Document Information	12 Months Ended
Document Information	Dec. 31, 2010
Document Type	10-K
Amendment Flag	false
Document Period End Date	Dec. 31, 2010

Entity Information	12 Months Ended
Entity Information	Dec. 31, 2010 USD ($)
Entity Registrant Name	REGENERON PHARMACEUTICALS INC
Entity Central Index Key	0000872589
Current Fiscal Year End Date	--12-31
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes
Entity Public Float	$ 1,726,149,000
Document Fiscal Period Focus	FY

Label	Element	Value
Class A [Member]
Conversion of Class A Stock to Common Stock (in shares)	us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	(11,000)
Conversion of Class A Stock to Common Stock (in shares)	us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	(4,000)
Conversion of Class A Stock to Common Stock (in shares)	us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities	(63,000)
Shares, Issued	us-gaap_SharesIssued	2,260,000
Shares, Issued	us-gaap_SharesIssued	2,249,000
Shares, Issued	us-gaap_SharesIssued	2,245,000
Shares, Issued	us-gaap_SharesIssued	2,182,000